Eli Lilly and Company

2026-06-02 18:47:00

This article compares two healthcare ETFs, XLV and RSPH, highlighting their contrasting investment strategies, operational costs, financial performance, and concentration levels. XLV (State Street Health Care Select Sector SPDR ETF) offers a market-cap-weighted approach with lower fees and higher dividend yield, focusing on large corporations. RSPH (Invesco S&P 500 Equal Weight Health Care ETF) uses an equal-weight strategy to diversify risk across the sector, albeit with higher fees and lower dividend yield.

2026-06-02 16:08:00

Eli Lilly has announced it will end 340B drug discount pricing for hospitals that have not complied with its claims data submission policy by June 8, drawing strong criticism from hospital industry groups. The company states that 70% of entities have already complied, dismissing arguments of undue burden and accusing large hospitals of boycotting transparency through trade associations. Hospital associations deem Lilly's policy unlawful and are calling for immediate federal intervention to prevent severe consequences for safety-net hospitals.

2026-06-02 15:45:20

Eli Lilly has issued an ultimatum to hospitals and medical groups participating in the 340B drug discount program, requiring them to comply with data sharing requirements by Monday or lose access to discounts on Lilly medications. The company asserts this is necessary to prevent double-dipping of discounts with other programs like Medicaid, while hospitals argue the demand is illegal and an attempt to limit 340B payments. This move follows Lilly's January announcement of the data requirement, which it had not yet enforced, and is part of a broader trend among major drugmakers seeking to reform and audit the 340B program.

2026-06-02 14:08:00

Eli Lilly and Company (LLY) is reportedly expanding into next-generation vaccines with a $1.55 billion acquisition of Vaccine Company, Inc., a clinical-stage biotech specializing in in vivo nanoparticle vaccine technology. This acquisition aims to develop vaccines for viral diseases, including an Epstein-Barr Virus candidate. Additionally, Eli Lilly recently released positive Phase 1b data for VERVE-102, an investigational gene-editing therapy for high LDL cholesterol, showing sustained lipid-lowering effects for up to 18 months.

2026-06-02 12:38:24

Pfizer is positioning 2026 as a pivotal year for its R&D pipeline, with significant investments in oncology, metabolic diseases, and vaccines, including M&A deals with Metsera and 3SBio. The company plans to initiate 20 pivotal studies in 2026, focusing on its obesity drug berobenatide (from Metsera) and a dual PD-1/VEGF inhibitor (from 3SBio) for oncology. These initiatives aim to drive new multi-billion-dollar franchises and reduce reliance on older products.

2026-06-02 12:10:44

This article compares two healthcare ETFs, the Fidelity MSCI Health Care Index ETF (FHLC) and the VanEck Pharmaceutical ETF (PPH), for investors looking to add healthcare exposure to their portfolios. FHLC offers broad sector diversification with a lower expense ratio, while PPH focuses on a more concentrated basket of pharmaceutical leaders, delivering higher returns and dividends over the last year and five years. Investors must weigh FHLC's stability and affordability against PPH's higher returns and concentration risk.